Eybelis ophthalmic solution 0.002%
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Normal Tension Glaucoma
Conditions
Normal Tension Glaucoma, Primary Open-angle Glaucoma, Glaucoma, Suspect, Ocular Hypertension
Trial Timeline
Feb 15, 2022 → Nov 20, 2023
NCT ID
NCT05279716About Eybelis ophthalmic solution 0.002%
Eybelis ophthalmic solution 0.002% is a approved stage product being developed by Santen Pharmaceutical for Normal Tension Glaucoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT05279716. Target conditions include Normal Tension Glaucoma, Primary Open-angle Glaucoma, Glaucoma, Suspect.
What happened to similar drugs?
3 of 5 similar drugs in Normal Tension Glaucoma were approved
Approved (3) Terminated (2) Active (2)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05279716 | Approved | UNKNOWN |
Competing Products
20 competing products in Normal Tension Glaucoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Roxadustat | Astellas Pharma | Phase 1 | 29 |
| Donepezil | Eisai | Approved | 43 |
| eribulin mesylate | Eisai | Phase 2 | 35 |
| Lurasidone HCl | Sumitomo Pharma | Phase 1 | 29 |
| Triptorelin | Merck | Pre-clinical | 26 |
| Temozolomide + Vorinostat | Merck | Phase 2 | 35 |
| LDE225 | Novartis | Phase 1 | 29 |
| LDK378 | Novartis | Phase 1 | 29 |
| cyclosporine micro-emulsion | Novartis | Approved | 35 |
| LDK378 | Novartis | Phase 1 | 29 |
| LEE011 | Novartis | Phase 1 | 29 |
| LEE011 | Novartis | Phase 1 | 29 |
| mycophenolate mofetil | Roche | Phase 1 | 29 |
| filgrastim | Amgen | Pre-clinical | 26 |
| PF-06423264 | Pfizer | Phase 1 | 21 |
| PF-05221304 | Pfizer | Phase 1 | 29 |
| BMS-933043 + Placebo matching with BMS-933043 + Antacid Buffer Predose Solution | Bristol Myers Squibb | Phase 1 | 29 |
| tolebrutinib | Sanofi | Phase 1 | 29 |
| Venglustat (GZ402671) | Sanofi | Phase 1 | 29 |
| Rilzabrutinib | Sanofi | Phase 1 | 29 |